“Moderna is well-prepared for the launch of its second respiratory vaccine, which will build upon the success of its commercial efforts in the fall COVID-19 market,” the company wrote.
Its second vaccine will be the “only pre-filled syringe” vaccine once it launches, which the drugmakers says will save pharmacists and clinicians time.
The FDA is expected to respond to Moderna’s RSV Biologics License Application by May 12. From there, if approved, it will move forward to the CDC’s Advisory Committee on Immunization Practices to be reviewed at its June meeting.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
